



# Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial

Jeroen Jaspers Focks,<sup>1</sup> Marc A Brouwer,<sup>1</sup> Daniel M Wojdyla,<sup>2</sup> Laine Thomas,<sup>2</sup> Renato D Lopes,<sup>2</sup> Jeffrey B Washam,<sup>3</sup> Fernando Lanas,<sup>4</sup> Denis Xavier,<sup>5</sup> Steen Husted,<sup>6</sup> Lars Wallentin,<sup>7</sup> John H Alexander,<sup>2</sup> Christopher B Granger,<sup>2</sup> Freek W A Verheugt<sup>1</sup>

<sup>1</sup>Department of Cardiology, Radboud University Nijmegen Medical Centre, PO box 9101, 6500 HB Nijmegen, Netherlands

<sup>2</sup>Duke Clinical Research Institute, Durham, NC, USA

<sup>3</sup>Duke Heart Center, Duke University Medical Center, Durham, NC, USA

<sup>4</sup>Department of Cardiology, Universidad de La Frontera, Temuco, Chile

<sup>5</sup>Department of Pharmacology and Clinical Research, St John's Medical College and Research Institute, Bangalore, India

<sup>6</sup>Department of Medicine, Hospital Unit West, Herning, Denmark

<sup>7</sup>Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden

Correspondence to: J Jaspers Focks [J.jaspersfocks@radboudumc.nl](mailto:J.jaspersfocks@radboudumc.nl)

Cite this as: *BMJ* 2016;353:i2868 <http://dx.doi.org/10.1136/bmj.i2868>

Accepted: 11 May 2016

## ABSTRACT

### OBJECTIVE

To determine whether the treatment effect of apixaban versus warfarin differs with increasing numbers of concomitant drugs used by patients with atrial fibrillation.

### DESIGN

Post hoc analysis performed in 2015 of results from ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation)—a multicentre, double blind, double dummy trial that started in 2006 and ended in 2011.

### PARTICIPANTS

18 201 ARISTOTLE trial participants.

### INTERVENTIONS

In the ARISTOTLE trial, patients were randomised to either 5 mg apixaban twice daily (n=9120) or warfarin (target international normalised ratio range 2.0-3.0; n=9081). In the post hoc analysis, patients were divided into groups according to the number of concomitant drug treatments used at baseline (0-5, 6-8, ≥9 drugs) with a median follow-up of 1.8 years.

### MAIN OUTCOME MEASURES

Clinical outcomes and treatment effects of apixaban versus warfarin (adjusted for age, sex, and country).

### RESULTS

Each patient used a median of six drugs (interquartile range 5-9); polypharmacy (≥5 drugs) was seen in

13 932 (76.5%) patients. Greater numbers of concomitant drugs were used in older patients, women, and patients in the United States. The number of comorbidities increased across groups of increasing numbers of drugs (0-5, 6-8, ≥9 drugs), as did the proportions of patients treated with drugs that interact with warfarin or apixaban. Mortality also rose significantly with the number of drug treatments (P<0.001), as did rates of stroke or systemic embolism (1.29, 1.48, and 1.57 per 100 patient years, for 0-5, 6-8, and ≥9 drugs, respectively) and major bleeding (1.91, 2.46, and 3.88 per 100 patient years, respectively). Relative risk reductions in stroke or systemic embolism for apixaban versus warfarin were consistent, regardless of the number of concomitant drugs (P<sub>interaction</sub>=0.82). A smaller reduction in major bleeding was seen with apixaban versus warfarin with increasing numbers of concomitant drugs (P<sub>interaction</sub>=0.017). Patients with interacting (potentiating) drugs for warfarin or apixaban had similar outcomes and consistent treatment effects of apixaban versus warfarin.

### CONCLUSIONS

In the ARISTOTLE trial, three quarters of patients had polypharmacy; this subgroup had an increased comorbidity, more interacting drugs, increased mortality, and higher rates of thromboembolic and bleeding complications. In terms of a potential differential response to anticoagulation therapy in patients with atrial fibrillation and polypharmacy, apixaban was more effective than warfarin, and is at least just as safe.

### TRIAL REGISTRATION

ARISTOTLE trial, ClinicalTrials.gov NCT00412984.

### Introduction

In an era of increasing life expectancy, and with a growing population of survivors with various comorbidities, clinical decision making with regard to antithrombotic therapy for atrial fibrillation has become an even greater clinical challenge.<sup>1</sup> Despite the well appreciated risk of stroke, oral anticoagulation is often not prescribed in older people, and undertreatment has been associated with adverse outcomes.<sup>2,3</sup> However, physicians increasingly acknowledge that treatment decisions should probably be based on biological age rather than chronological age.<sup>4</sup>

In various populations, polypharmacy has been associated with multiple comorbidities and frailty.<sup>5-10</sup> Moreover, the risk of drug-drug interactions increases

## WHAT IS ALREADY KNOWN ON THIS TOPIC

Polypharmacy is associated with increased comorbidity, frailty, and drug-drug interactions, and has repeatedly been shown to be a marker of adverse clinical outcome; therefore, patients with polypharmacy could have a differential response to anticoagulation therapy

For patients with atrial fibrillation, apixaban has been more effective and safer than warfarin, but whether this also holds true for patients using many concomitant drugs is unknown

## WHAT THIS STUDY ADDS

For patients with atrial fibrillation, apixaban was more effective than warfarin regardless of the number of concomitant drugs used

Although major bleeding rates were consistently lower with apixaban than with warfarin, the magnitude of benefit with apixaban seemed to decrease with the increasing number of concomitant drug treatments

In this patient group, the specific use of warfarin or apixaban potentiating drugs did not seem to account for this differential response to anticoagulation therapy with regard to major bleeding

with the number of concomitant drug treatments. In addition, polypharmacy has been related to a higher risk of death and bleeding complications, also in patients with atrial fibrillation.<sup>6-17</sup> In this context, patients with polypharmacy could have a differential response to anticoagulation therapy.

With the introduction of apixaban, a safer alternative to warfarin has become available that has also proven to be of value in patients considered unsuitable for warfarin treatment.<sup>18 19</sup> In a previous report, we demonstrated that the benefits of apixaban versus warfarin were irrespective of age (<65 years *v* 65-74 years *v* ≥75 years).<sup>20</sup> However, among the elderly population, there are patients with hardly any comorbidity, whereas there are also younger patients with clinically significant comorbidity. On average, patients with atrial fibrillation use about four to six different drug treatments.<sup>10-21</sup> Given that polypharmacy is generally defined as the use of five or more concomitant drug treatments, and thus represents an everyday issue, additional information on the effect of oral anticoagulation drugs in this subset of patients is of clinical importance.<sup>22</sup> Especially in the case of apixaban, information on the effect of potentiating drugs is limited, and is of interest in patients treated with many concomitant drugs.

In this context, we performed a post hoc analysis of the ARISTOTLE trial (apixaban for reduction of stroke and other thromboembolic events in atrial fibrillation) to assess the association between the number of drugs used and the extent of comorbidity and adverse outcome.<sup>19</sup> In addition, we looked at the relative treatment effect of apixaban versus warfarin in relation to the number of concomitant drug treatments.

## Methods

### Patients

The study design and main outcomes of the ARISTOTLE trial have been reported previously.<sup>19 23</sup> In brief, ARISTOTLE was a multicentre, double blind, double dummy trial comparing apixaban with warfarin performed in 2006-11. Patients with documented atrial fibrillation or atrial flutter were eligible for inclusion if one or more of the following risk factors for thromboembolism were present: symptomatic heart failure within three months before inclusion or left ventricular function 40% or less; hypertension requiring pharmacological treatment; age 75 years or older; diabetes mellitus; and prior stroke, transient ischaemic attack, or systemic embolus.

Exclusion criteria included clinically significant mitral stenosis, conditions other than atrial fibrillation requiring anticoagulation, required aspirin treatment in a dose more than 165 mg/day or used in combination with a thienopyridine, recent ischaemic stroke, atrial fibrillation due to reversible causes, an increased bleeding risk considered to be a contraindication for oral anticoagulation, and severe renal insufficiency (that is, serum creatinine >221.0 μmol/L or calculated creatinine clearance <0.42 mL/s).

Patients were randomised to either 5 mg apixaban twice daily (n=9120) or a dose adjusted regimen of

warfarin (n=9081). The target range for the international normalised ratio was 2.0 to 3.0, using a blinded encrypted point of care device. If two or more of the following criteria were present at baseline, patients received an apixaban dose of 2.5 mg twice daily or matching placebo: age 80 years or older, body weight up to 60 kg, serum creatinine 132.6 μmol/L or more. The study was approved by appropriate ethical committees at all sites and all patients provided written informed consent.

### Concomitant drug treatments and comorbidity

To investigate the association between the number of concomitant drugs and the extent of comorbidity, we assessed the number of drugs used for each patient. The study drug (apixaban or warfarin) and the matching placebo were counted as one drug. All treatments were categorised by drug class, according to the Anatomical Therapeutic Chemical classification system.<sup>24</sup> Polypharmacy was defined as the use of five or more concomitant drugs.<sup>22</sup>

The use of drugs known to interact with apixaban or warfarin was assessed for each patient. For apixaban, we studied drugs known to inhibit both the cytochrome P450 (CYP) 3A4 enzyme as well as the P-glycoprotein as depicted by the US Food and Drug Administration.<sup>25</sup> For warfarin, we studied the use of drugs known to inhibit or potentiate its anticoagulant effect with a high probability according to the American College of Chest Physicians guideline.<sup>26</sup>

All analyses performed were based on the baseline medication burden. Only for the anticoagulant we studied premature permanent discontinuation of the study drug; for patients assigned to warfarin, we calculated the time in therapeutic range according to the Rosendaal method.<sup>27</sup>

Per protocol—the use of any concomitant drugs during the trial—was left to the discretion of the treating physician. The following concomitant drugs were prohibited in combination with the study drug: potent inhibitors of CYP3A4 (eg, azole antifungals, macrolide antibiotics, protease inhibitors, and nefazadone), aspirin taken as a daily dose of more than 165 mg, other anticoagulant agents (eg, unfractionated heparin, low molecular weight heparin, direct thrombin inhibitors, pentasaccharides), and glycoprotein IIb/IIIa inhibitors. If these agents were used during trial participation, the study drug was to be (temporarily) interrupted and restarted as soon as the prohibited drug was discontinued. During the trial, it was also advised to cautiously use aspirin in combination with a thienopyridine, chronic daily use of a non-steroid anti-inflammatory agent, and cytotoxic or myelosuppressive therapy.

### Clinical outcomes

We assessed outcomes in relation to the number of concomitant drug treatments used at the time of randomisation, during a median follow-up of 1.8 years (interquartile range 1.3-2.3 years). The primary efficacy outcome was stroke (that is, abrupt onset of focal

neurological symptoms lasting at least 24 h) or a systemic embolism (that is, symptoms suggestive of an acute loss of blood flow to a non-cerebral artery, supported by evidence of embolism from surgical specimens, autopsy, angiography, or other objective testing). Key secondary efficacy outcomes included assessment of the type of stroke (ischaemic, haemorrhagic, or unspecified) and all cause death.

The primary safety endpoint was major bleeding according to the criteria set by the International Society on Thrombosis and Haemostasis, which includes any clinically overt bleeding event accompanied by one or more of the following: haemoglobin drop of 20 g/L or more over a 24 h period, transfusion of two or more units of packed red blood cells, bleeding at a critical site (that is, intracranial, intraspinal, intraocular, intra-articular, pericardial, intramuscular with compartment syndrome, or retroperitoneal), or fatal bleeding.<sup>28</sup> Moreover, clinically relevant non-major bleeding events were monitored, and were defined as all clinically overt bleeding not meeting the criteria of major bleeding but leading to hospital admission, physician guided medical or surgical treatment, or a change in anti-thrombotic therapy. We defined the combined endpoint of net benefit as the combination of death, stroke, systemic embolism, and major bleeding.

### Statistical analysis

This post hoc analysis of ARISTOTLE was performed in 2015. Based on the tertiles of the distribution of the number of concomitant drugs used at baseline (that is, 0-5, 6-8, and  $\geq 9$  drugs), patients were classified in groups. Comorbidities, organised by organ system, were summarised for the three groups, as well as other baseline characteristics. A similar approach was followed for the different drug classes. Data were depicted as means and standard deviations for continuous variables and frequencies and percentages for categorical variables. We used one way analysis of variance and  $\chi^2$  tests to compare groups. Efficacy, safety, and net benefit endpoints were compared among the three groups using rates per 100 patient years of follow-up and adjusted hazard ratios with 95% confidence intervals. Adjusted hazard ratios were derived using Cox regression models adjusting for sex and age and country of randomisation. In these models, age was considered non-linear and included as a restricted cubic spline. We assessed the randomised treatment effect within each group (0-5, 6-8,  $\geq 9$  drugs) using a Cox regression model to estimate hazard ratios for apixaban versus warfarin along with 95% confidence intervals. The homogeneity of the randomised treatment effect across groups was tested by adding interaction terms to the Cox regression model.

The proportional hazard assumption was evaluated using scaled Schoenfeld residuals and no clinically relevant departure from the assumption was observed. All the analyses were performed with SAS version 9.4 (SAS Institute).

### Patient involvement

No patients were involved in designing the study, in assessing the burden of the intervention on patients, or in explicitly setting outcome measures; however, outcomes were chosen to reflect daily practice described in earlier studies.<sup>29</sup> Final study results of the ARISTOTLE trial were disseminated to study participants through their treating physicians.

### Results

#### Baseline characteristics and comorbidity

Table 1 depicts baseline characteristics of the study population, categorised by groups of the number of drug treatments. The randomised treatment was well balanced across groups, and no relevant differences between apixaban and warfarin was observed for any of the drug categories across the population (supplementary table 1).

Patients using more drug treatments were older, more often female, and less often warfarin naive at study entry (table 1). The CHADS<sub>2</sub> and HAS-BLED scores increased with the increasing number of concomitant drug treatments. With the increasing number of drugs, the associated comorbidity increased significantly (table 1).

#### Concomitant drugs—classification according to organ or system

The median number of drug treatments used was six (interquartile range 5-9) and polypharmacy was present in 13 932 (76.5%) patients (supplementary fig 1). Among the 18 201 ARISTOTLE participants, we saw marked regional differences in the number of drugs used: 53% (2385/4474) of patients enrolled in North America used nine or more drugs (United States 1980/3417 (58%); Canada 405/1057 (38%)), compared with 10-21% for the other regions (table 1). Although there were more patients with comorbidity in four or more organ systems in the USA than in non-US countries (1389 (43.3%) v 2602 (20.5%)), we observed a greater number of drugs used in the USA regardless of the number of comorbidities.

Across groups of increasing number of drugs, the median number of represented drug classes increased from two (interquartile range two to three) to five (four to five), for patients using up to five drugs and for those using nine or more drugs, respectively.

Across the three study groups, there were no relevant differences between apixaban and warfarin regarding the proportion of patients in each of the defined drug classes. For each of the respective drug classes, the proportion of patients increased statistically significantly from the group using up to five concomitant drugs to the group using nine or more concomitant drugs. Across groups of increasing concomitant medication, the proportion of patients in the respective drug classes was higher in the USA than in non-US countries (supplementary table 2A and 2B). Despite this difference in prescription pattern, we saw a clear association between the number of concomitant drugs used at baseline and the number of comorbidities, both for the US and non-US populations.

Table 1 | Baseline characteristics of ARISTOTLE trial participants, by number of concomitant drugs used

Characteristic	No of drugs			P
	0-5 (n=6943)	6-8 (n=6502)	≥9 (n=4756)	
Age (years, mean (SD))	68 (10)	69 (10)	71 (9)	<0.001
Male	4687 (67.5)	4107 (63.2)	2991 (62.9)	<0.001
Weight (kg, mean (SD))	81 (19)	84 (21)	89 (23)	<0.001
Body mass index (mean (SD))	28.2 (5.4)	29.5 (6.0)	30.7 (6.5)	<0.001
Previous use of vitamin K antagonists >30 days	3555 (51.2)	3656 (56.2)	3190 (67.1)	<0.001
Creatinine (mg/dL, mean (SD))	1.02 (0.24)	1.06 (0.28)	1.12 (0.32)	<0.001
Region of enrolment				
North America	736 (10.6)	1353 (20.8)	2385 (50.1)	<0.001
Latin America	1809 (26.1)	1306 (20.1)	353 (7.4)	
Europe	3128 (45.1)	2811 (43.2)	1404 (29.5)	
Asia	1270 (18.3)	1032 (15.9)	614 (12.9)	
HAS-BLED score (mean (SD))	1.45 (0.96)	1.77 (1.02)	2.25 (1.05)	<0.001
CHADS <sub>2</sub> score (mean (SD))	1.87 (1.02)	2.15 (1.08)	2.44 (1.17)	<0.001
CHADS <sub>3</sub> score				
≤1	3093 (44.5)	2057 (31.6)	1033 (21.7)	<0.001
2	2309 (33.3)	2400 (36.9)	1807 (38.0)	
≥3	1541 (22.2)	2045 (31.5)	1916 (40.3)	
Randomised group				
Apixaban	3424 (49.3)	3320 (51.1)	2376 (50.0)	0.13
Warfarin	3519 (50.7)	3182 (48.9)	2380 (50.0)	
Low dose apixaban/placebo received (2.5 mg twice daily)	253 (3.6)	288 (4.4)	290 (6.1)	<0.001
Cardiovascular comorbidities				
Coronary artery disease	1795 (25.9)	2184 (33.6)	2063 (43.4)	<0.001
Prior myocardial infarction	564 (8.1)	985 (15.2)	1036 (21.8)	<0.001
History of percutaneous coronary intervention or coronary artery bypass grafting	369 (5.3)	815 (12.5)	1292 (27.2)	<0.001
Congestive heart failure within 3 months	1931 (27.8)	2194 (33.7)	1416 (29.8)	<0.001
At least moderate valvular heart disease	926 (13.4)	1192 (18.3)	1116 (23.5)	<0.001
Syncope in past 5 years	258 (3.7)	279 (4.3)	322 (6.8)	<0.001
Hypertension with pharmacological treatment	5844 (84.2)	5762 (88.6)	4310 (90.6)	<0.001
Peripheral artery disease	193 (2.8)	290 (4.5)	401 (8.5)	<0.001
Aortic aneurysm	46 (0.7)	84 (1.3)	139 (3.0)	<0.001
Neurological/cerebrovascular comorbidities				
Carotid stenosis	54 (0.8)	93 (1.4)	190 (4.0)	<0.001
Transient ischaemic attack	302 (4.4)	315 (4.8)	337 (7.1)	<0.001
Stroke	808 (11.6)	750 (11.5)	569 (12.0)	0.77
Dementia	22 (0.4)	29 (0.5)	45 (1.0)	<0.001
Epilepsy	22 (0.4)	49 (0.8)	41 (0.9)	<0.001
Pulmonary comorbidities				
Chronic obstructive pulmonary disease	435 (6.3)	626 (9.7)	889 (18.7)	<0.001
Asthma	157 (2.3)	250 (3.9)	462 (9.7)	<0.001
Sleep Apnoea	145 (2.1)	262 (4.0)	606 (12.8)	<0.001
Gastrointestinal comorbidities				
Dyspepsia	374 (5.4)	445 (6.9)	556 (11.7)	<0.001
Gastroesophageal reflux disease	315 (4.5)	527 (8.1)	1074 (22.6)	<0.001
Peptic ulcer disease	383 (5.5)	417 (6.4)	406 (8.5)	<0.001
Gastrointestinal surgery	509 (7.3)	606 (9.3)	575 (12.1)	<0.001
Chronic liver disease	190 (2.7)	193 (3.0)	121 (2.5)	0.39
Endocrine comorbidities				
Hypothyroidism or hyperthyroidism	429 (6.2)	733 (11.3)	878 (18.5)	<0.001
Diabetes mellitus	806 (11.6)	1603 (24.7)	2138 (45.0)	<0.001
End organ damage due to diabetes mellitus	75 (1.1)	219 (3.4)	459 (9.7)	<0.001
Musculoskeletal comorbidities				
Falls within 1 year	140 (2.3)	215 (3.6)	398 (8.8)	<0.001
Previous non-traumatic fracture	299 (4.3)	339 (5.2)	436 (9.2)	<0.001
Osteoporosis	151 (2.2)	298 (4.6)	521 (11.0)	<0.001
Renal comorbidities				
Chronic kidney disease	434 (6.3)	520 (8.0)	553 (11.6)	<0.001
Creatine clearance <50 mL/min	927 (13.4)	1112 (17.2)	970 (20.5)	<0.001

(Continued)

**Table 1 | Baseline characteristics of ARISTOTLE trial participants, by number of concomitant drugs used**

Characteristic	No of drugs			P
	0-5 (n=6943)	6-8 (n=6502)	≥9 (n=4756)	
Haematological comorbidities				
History of Anemia	210 (3.0)	359 (5.5)	676 (14.2)	<0.001
Thrombocytopenia (platelet at baseline <150×10 <sup>9</sup> /L)	510 (7.6)	467 (7.4)	332 (7.2)	0.77
Bleeding history	779 (11.2)	1029 (15.8)	1232 (25.9)	<0.001
No of organ systems affected (median (IQR))	2, 1-3	2, 2-3	3, 2-4	<0.001

Data are no (%) of patients unless stated otherwise. Subcategorisation of all baseline characteristics per treatment allocation is presented in web table 1. CHADS<sub>2</sub>=congestive heart failure, hypertension, age (≥75 years), diabetes mellitus, and previous stroke/transient ischaemic attack/systemic embolism (doubled risk weight); HAS-BLED=uncontrolled hypertension, abnormal renal and liver function, prior stroke, bleeding history (or predisposition), labile international normalised ratio, age>65 years, drugs predisposing to bleed, and alcohol use disorders; IQR=interquartile range; SD=standard deviation.

## Clinical outcomes according to the number of concomitant drugs

### Efficacy outcomes

With regard to the primary efficacy endpoint (stroke and systemic embolism), patients using more concomitant drugs were at higher risk, with an increase in event rates from 1.29 per 100 patient years for patients using up to five drugs to 1.57 per 100 patient years for patients using nine or more drugs (P<0.001; table 3). For the secondary efficacy outcomes, there was also a significant association with the number of concomitant drugs. We saw a twofold increased risk for all cause death for patients using nine concomitant drugs or more compared with those using up to five concomitant drugs (P<0.001).

### Safety outcomes

The risk of major bleeding for patients using six or more concomitant drugs was significantly higher than for those using up to five drugs (using 0-5 drugs as reference group; 6-8 drugs: adjusted hazard ratio 1.24 (95% confidence interval 1.04 to 1.49); ≥9 drugs: 1.72 (1.41 to 2.10); table 3). When subdividing major bleeding according to the location, we observed no significant difference

across groups for intracranial bleeding (P=0.73), while the event rate for gastrointestinal bleeding significantly increased with a higher number of concomitant drugs.

### Net benefit outcome

With regard to the combined endpoint of stroke, systemic embolism, major bleeding, and all cause death, event rates increased across groups (5.24, 6.59, and 8.92 per 100 patient years for 0-5, 6-8, and ≥9 drugs, respectively, P<0.001; table 3). This increase was associated with an adjusted hazard ratio of 1.84 (95% confidence interval 1.63 to 2.07) for patients using at least nine concomitant drugs compared with those using up to five concomitant drugs (table 3).

### Other outcomes

With the use of increasing numbers of concomitant drugs, the risk of permanent discontinuation of study drug rose significantly (discontinuation rates 14.3, 15.0, and 17.4 per 100 patient years at risk for 0-5, 6-8, and ≥9 drugs, respectively, P<0.001; table 3). Poor control of the international normalised ratio during follow-up (that is, time in therapeutic range <66%) was highest in the

**Table 2 | Distribution of drug classes used by ARISTOTLE trial participants, by number of concomitant drugs used**

Drug class	No of drugs			P
	0-5 (n=6943)	6-8 (n=6502)	≥9 (n=4756)	
Alimentary tract and metabolism	962 (13.9)	3045 (46.8)	4094 (86.1)	<0.001
Blood and blood forming organs (excluding apixaban/warfarin)	2282 (32.9)	4322 (66.5)	4116 (86.5)	<0.001
Cardiovascular system	6460 (93.0)	6468 (99.5)	4737 (99.6)	<0.001
Dermatological drugs	34 (0.5)	96 (1.5)	346 (7.3)	<0.001
Genitourinary system and sex hormones	173 (2.5)	510 (7.8)	936 (19.7)	<0.001
Systemic hormonal preparations, excluding sex hormones and insulins	181 (2.6)	508 (7.8)	852 (17.9)	<0.001
Anti-infective drugs for systemic use	44 (0.6)	161 (2.5)	347 (7.3)	<0.001
Antineoplastic and immunomodulating agents	14 (0.2)	60 (0.9)	152 (3.2)	<0.001
Musculoskeletal system	202 (2.9)	688 (10.6)	1350 (28.4)	<0.001
Nervous system	523 (7.5)	1448 (22.3)	2376 (50.0)	<0.001
Antiparasitic products, insecticides, and repellents	0 (0.0)	13 (0.2)	46 (1.0)	<0.001
Respiratory system	164 (2.4)	600 (9.2)	1336 (28.1)	<0.001
Sensory organs	41 (0.6)	115 (1.8)	300 (6.3)	<0.001
Various	126 (1.8)	247 (3.8)	630 (13.2)	<0.001
Interacting drugs				
≥1 combined P-glycoprotein and weak-moderate-strong CYP3A4 inhibitor	1128 (16.2)	1431 (22.0)	1301 (27.4)	<0.001
≥1 combined P-glycoprotein and weak-moderate-strong CYP3A4 inducer	12 (0.2)	34 (0.5)	47 (1.0)	<0.001
≥1 highly probable VKA inhibiting drug	8 (0.1)	19 (0.3)	33 (0.7)	<0.001
≥1 highly probable VKA potentiating drug	973 (14.0)	1406 (21.6)	1387 (29.2)	<0.001
Use of acetylsalicylic acid, NSAIDs, or prednisone	956 (13.8)	2064 (31.7)	2362 (49.7)	<0.001

Data are no (%) of patients. CYP=cytochrome P450; VKA=vitamin K antagonist, NSAIDs=non-steroidal anti-inflammatory drugs.

Table 3 | Efficacy and safety outcomes by number of concomitant drug treatments used by ARISTOTLE trial participants

Event	0-5 drugs		6-8 drugs		≥9 drugs		P
	Rate per 100 patient years (no of patients)	Adjusted hazard ratio (95% CI)	Rate per 100 patient years (no of patients)	Adjusted hazard ratio (95% CI)	Rate per 100 patient years (no of patients)	Adjusted hazard ratio (95% CI)	
<b>Efficacy outcomes</b>							
Stroke/SE	1.29 (166)	Reference	1.48 (176)	1.270 (1.022 to 1.577)	1.57 (135)	1.539 (1.190 to 1.991)	0.004
Ischaemic or uncertain type of stroke	0.82 (106)	Reference	1.11 (132)	1.475 (1.136 to 1.915)	1.15 (99)	1.738 (1.275 to 2.369)	0.001
All cause death	3.01 (396)	Reference	3.80 (462)	1.409 (1.229 to 1.616)	4.70 (414)	2.031 (1.735 to 2.377)	<0.001
<b>Safety outcomes</b>							
Major bleeding	1.91 (224)	Reference	2.46 (267)	1.243 (1.036 to 1.491)	3.88 (298)	1.721 (1.414 to 2.095)	<0.001
Intracranial	0.54 (64)	Reference	0.55 (61)	1.025 (0.722 to 1.456)	0.62 (49)	1.153 (0.795 to 1.673)	0.73
Gastrointestinal	0.47 (56)	Reference	0.71 (78)	1.498 (1.062 to 2.111)	1.15 (90)	2.429 (1.740 to 3.391)	<0.001
Clinically relevant non-major bleeding	2.09 (243)	Reference	2.47 (267)	1.183 (0.994 to 1.408)	3.30 (252)	1.574 (1.319 to 1.877)	<0.001
Any bleeding	17.41 (1742)	Reference	21.40 (1908)	1.167 (1.092 to 1.247)	29.63 (1766)	1.452 (1.348 to 1.565)	<0.001
<b>Net benefit outcomes</b>							
Stroke/SE/major bleeding/all cause death	5.24 (665)	Reference	6.59 (769)	1.320 (1.187 to 1.468)	8.92 (743)	1.838 (1.631 to 2.071)	<0.001
<b>Other outcomes</b>							
Permanent study drug discontinuation	14.32 (1699)	Reference	14.99 (1655)	1.053 (0.982 to 1.129)	17.44 (1372)	1.218 (1.123 to 1.322)	<0.001
Time in therapeutic range <66%*	53.2 (1823)	Reference	50.2 (1564)	0.887 (0.805 to 0.977)	44.9 (1044)	0.716 (0.644 to 0.795)	<0.001

Hazard ratios and P values adjusted by country (strata), sex, and age (spline). SE=systemic embolism.

\*Values reported are percentage (number of patients) and unadjusted odd ratios for patients randomised to warfarin.

patients using up to five concomitant drugs and decreased across the groups (53.2%, 50.2%, and 44.9% for 0-5, 6-8, and ≥9 drugs, respectively,  $P<0.001$ ; table 3).

### Treatment effect

Figures 1 and 2 outline the treatment effect of apixaban versus warfarin for the different study outcomes, categorised by the number of concomitant drugs used at baseline.

For the primary efficacy outcome, risk reductions of apixaban versus warfarin were consistent, irrespective of the number of concomitant drugs used ( $P_{\text{interaction}}=0.82$ ), with lower event rates on apixaban for all groups. Also for the secondary efficacy outcomes, no significant interactions were observed.

With regard to major bleeding, relative risk reductions for apixaban versus warfarin fell with increasing number of concomitant drugs ( $P_{\text{interaction}}=0.017$ ), corresponding to absolute rate reductions per 100 patient years of 1.28, 0.82, and 0.66 for the three groups (0-5, 6-8, and ≥9 drugs, respectively). For intracranial bleeding, the absolute benefit on apixaban showed a numerical increase across the groups, by contrast with the numerical differences in major gastrointestinal bleeding observed between treatment groups. With regards to the combined outcome of stroke, systemic embolism, major bleeding, and all cause death, we observed no significant interaction between treatment groups ( $P=0.10$ ). Rates of permanent study drug discontinuation were lower for apixaban in all groups ( $P_{\text{interaction}}=0.36$ ).

### Interacting drugs

The proportion of patients using an interacting drug increased across the groups of concomitant drug treatments, both for CYP3A4 and P-glycoprotein inhibitors as warfarin potentiating drugs. At least one combined inhibitor of both the CYP3A4 enzyme and P-glycoprotein

was used by 20.9% (1903/9120) of patients treated with apixaban, and 21.1% (1913/9081) of patients treated with warfarin used vitamin K antagonist potentiating drugs. For the concomitant use of aspirin, non-steroidal anti-inflammatory drugs, or prednisone, proportions were 13.8%, 31.7%, and 49.7% for the three groups (0-5, 6-8, and ≥9 drugs, respectively;  $P<0.001$ ).


Rates of major bleeding did not significantly differ between patients with or without combined CYP3A4 and P-glycoprotein inhibitors (2.59 v 2.61 per 100 patient years, respectively). Moreover, no significant interaction with the treatment allocation was observed ( $P=0.39$ ; table 4). With regard to drugs known to potentiate warfarin, we also observed no difference in the event rate of major bleeding for users versus non-users (2.60 v 2.61 per 100 patient years).

### Discussion

In this post hoc analysis of the ARISTOTLE trial, we observed that polypharmacy was present in three quarters of patients and that the number of concomitant drug treatments is associated with increased comorbidity. Prescription patterns differed across regions, with about twice the number of concomitant drugs used in the USA versus non-US countries. Adverse clinical outcomes occurred more frequently in patients treated with a higher number of concomitant drugs. The benefits of apixaban in reducing stroke were preserved, regardless of the number of concomitant drugs taken. In terms of safety, although rates of major bleeding were consistently lower with apixaban than with warfarin, the magnitude of benefit with apixaban decreased with the increasing number of concomitant drug treatments.

### Polypharmacy and adverse outcomes

Atrial fibrillation affects older patients, who have a varying extent of comorbidity and associated concomitant



**Fig 1 | Association between randomised treatment and main outcomes, by number of concomitant drugs used at baseline by ARISTOTLE trial participants**

drug treatments.<sup>30</sup> Previous studies have reported rates of polypharmacy in 40–64% of patients with atrial fibrillation, with varying prescription patterns and inclusion and exclusion criteria.<sup>9,10</sup>

Various reports have demonstrated, for different clinical conditions, that polypharmacy is associated with increased comorbidity.<sup>5–10</sup> In addition, studies focusing on older populations have linked polypharmacy to adverse drug reactions, falls, disability, and frailty.<sup>6–8</sup> In this context, patients with polypharmacy could constitute a population with a differential response to oral anticoagulation.

Although differences in prescription thresholds could affect the classification of patients in individual

cases, several reports have repeatedly demonstrated on a group level that polypharmacy is associated with comorbidity and adverse outcome, also in populations with atrial fibrillation.<sup>6–17</sup> Our findings of higher risks of bleeding, stroke, and all cause mortality with increasing numbers of drugs are in line with these previous observations.

Notably, this increased risk of adverse outcomes should be placed in the context of the association between the number of drug treatments and comorbidities present at baseline, indicating a more frail status of patients with polypharmacy. If we were to adjust for these baseline differences, it is likely that the risk of adverse outcomes related to the number of drugs would diminish. However, we did not study the association between polypharmacy and adverse outcomes independent of the baseline difference. On the contrary, we studied the number of concomitant drugs as a marker of comorbidity or frailty, and adverse outcome.

As such, we performed adjustments limited to age, sex, and country of randomisation. It was important to adjust for region, given the differences in prescription patterns between countries that are independent of differences in comorbidity. It is striking that the USA had more use of polypharmacy than non-US countries, which was not solely explained by comorbidity.

#### Polypharmacy and treatment effect

Considering that patients with polypharmacy have a higher risk of adverse outcomes and multiple coexisting impairments, it is of special interest to study whether the main trial results of the ARISTOTLE study are consistent among patients using many concomitant drug treatments. For the primary endpoint of stroke and systemic embolism, we saw an absolute risk reduction from 1.60% per year with warfarin to 1.27% per year with apixaban (21% relative risk reduction in the complete population, which was consistent irrespective of the number of concomitant drugs used).<sup>19</sup>

Overall, the use of apixaban was associated with an absolute risk reduction in major bleeding from 3.09% to 2.13% per year when compared with warfarin (relative risk reduction 31%).<sup>19</sup> However, we observed a significant treatment interaction with relative risk reductions of apixaban varying from 50% (0–5 drugs) to 28% (6–8 drugs) and 16% (≥9 drugs), respectively. Importantly, the risk reduction of intracranial bleeding did not diminish with an increasing number of concomitant drugs. Therefore, the fact that the relative benefit of apixaban over warfarin appears to diminish across groups is due to other types of major bleeding. For example, with increasing numbers of drug treatments, the numerical difference in gastrointestinal bleeding events shifts from a benefit for apixaban (0–5 drugs) to no apparent difference (≥9 drugs) between both oral anticoagulants.

The ROCKET AF trial, with overall similar rates of major bleeding for rivaroxaban and warfarin, also showed a treatment interaction for major bleeding.<sup>10</sup> The hazard ratio for major bleeding in patients using fewer concomitant drugs (0–4) was lower than that




Fig 2 | Treatment comparisons for efficacy, safety, and net benefit outcomes between apixaban and warfarin according to the number of concomitant drugs used by ARISTOTLE trial participants at baseline

observed in the entire study population (adjusted hazard ratio 0.69 (95% confidence interval 0.51 to 0.94) v 1.04 (0.90 to 1.20)). For mortality, there was no difference in treatment effect of rivaroxaban in patients with polypharmacy. In the ARISTOTLE trial, apixaban reduced the risk of mortality from 3.94% to 3.52% per year when compared with warfarin in the main study—a relative risk reduction of 11% that was consistent regardless of the number of concomitant drug treatments.<sup>19</sup>

In the ARISTOTLE trial as well as in the ROCKET AF trial, patients with polypharmacy were older.<sup>10</sup> Nonetheless, the relative reduction of both apixaban and rivaroxaban on major bleeding proved to be consistent

across the different age groups in previously reported post hoc analyses.<sup>20-31</sup> Importantly, this implies that our findings cannot be inferred to older patients in general. In fact, our findings are irrespective of age and sex, and refer to the group of patients, both younger and older, with multiple comorbidities and drug treatments.

Possible explanations for the attenuation of the observed safety benefit of apixaban with increasing concomitant drugs include effects of comorbidity and drug-drug interactions, or the play of chance. We demonstrated that various coexisting diseases (chronic obstructive pulmonary disease, gastrointestinal disease, renal impairment) were more frequent with increasing numbers of concomitant drugs. Of interest,



**Table 4 | Major bleeding rates with apixaban or warfarin according to use of interacting drugs by ARISTOTLE trial participants**

Interacting drugs	Use of potentiating drug (rate per 100 patient years (no of patients))		No use of potentiating drug (rate per 100 patient years (no of patients))		P <sub>interaction</sub>
	Apixaban	Warfarin	Apixaban	Warfarin	
≥ 1 combined P-glycoprotein and weak/moderate/strong CYP3A4 inhibitor	2.27 (72)	2.91 (93)	2.10 (255)	3.14 (369)	0.39
≥ 1 highly probable VKA potentiating drug	2.03 (62)	3.16 (96)	2.16 (265)	3.07 (366)	0.64

CYP=cytochrome P450; VKA=vitamin K antagonist.

given the consistent risk reduction of apixaban for intracranial bleeding, the treatment interaction for major bleeding is related to other major bleeding. Risk factors for gastrointestinal bleeding complications (eg, previous gastric ulcers; gastrointestinal surgery; dyspepsia; use of aspirin, prednisone, or non-steroidal anti-inflammatory drugs) were more prevalent among patients with polypharmacy. Other non-gastrointestinal risk factors for bleeding were also more often common in patients using more concomitant drugs (eg, older age, renal impairment, anaemia, diabetes, and previous bleeding).<sup>32</sup>

Other aspects that could account for the reduced benefit of apixaban in patients using nine concomitant drugs or more are the higher rates of permanent study drug discontinuation and lower proportion of patients who were vitamin K antagonist naive (supplementary table 1).<sup>33</sup> The lower rates of patients on study medication may have blunted the observed risk reduction of apixaban in this group. In addition, bleeding rates on warfarin are usually lower in patients with prior experience vitamin K antagonists. Finally, the better control of international normalised ratio in the patients with more than nine concomitant drug treatments may have diminished bleeding rates on warfarin.<sup>34 35</sup>

For drug-drug interactions, we specifically studied the effect of warfarin potentiating drugs and the combination of CYP3A4 and P-glycoprotein inhibitors, given the possibility of higher plasma concentrations of apixaban with these agents. However, we saw no evidence of differential treatment effect between apixaban and warfarin across groups of the number of concomitant drugs when accounting for warfarin or apixaban potentiating drugs.

The effects of non-vitamin K antagonist oral anticoagulants in patients with polypharmacy have also been studied in a pooled analysis of data, in the setting of secondary prevention after a venous thromboembolism.<sup>15</sup> For major bleeding, there was no treatment interaction when comparing the safety of dabigatran versus warfarin in patients using three or fewer concomitant drugs with those using more than three concomitant drugs. However, these patients were much younger and less fragile than patients with atrial fibrillation.

With regards to symptomatic venous thromboembolism, the issue of a potential different response to oral anticoagulation therapy in patients considered to be fragile has been studied in more detail.<sup>36</sup> In this study, patients were considered to be fragile if they were over 75 years old, had a low body weight (<50 kg), or had impaired renal function (creatinine clearance <0.83 mL/s). Although

this certainly identifies patients at risk, incorporation of multiple comorbidities would allow for a more refined identification of frail patients within these specific subgroups.<sup>37</sup>

In summary, polypharmacy could be a marker of multimorbidity and a predictor of adverse outcomes, and it might provide a first general impression of a patient's frailty. Future research on a differential response with oral anticoagulation therapy in patients with multimorbidity should focus on incorporation of the key frailty criteria. For example, the Fried criteria can help to identify higher risk patients who are often under-represented in clinical trials.<sup>38</sup> This group may deserve additional attention, as far as the generalisability of trial data is concerned, not only in the field of anticoagulation therapy but also for other treatments.<sup>39</sup>

#### Study limitations

This study had several limitations. Firstly, it was a post hoc analysis, although there was a prospective, detailed analysis plan. Secondly, the analyses were based on the drug burden at baseline, without information on drug changes, reason, or appropriateness of drug prescription. However, with polypharmacy that is often driven by chronic medical conditions, substantial reductions in the number of drugs are not likely. Thirdly, as the number of drugs might not only be driven by the extent of comorbidity, but also by prescription patterns, we acknowledge that this might have affected classification on an individual level. However, on a group level, the use of polypharmacy has repeatedly demonstrated to be a marker of the extent of comorbidity and associated with adverse outcome.

The cut-off value of five or more drugs is arbitrary, although it has been used in many previous reports. Given that three quarters of patients would qualify for polypharmacy according to this definition, our statistical approach was not arbitrary, but based on a common approach of dividing our data into groups to explore polypharmacy across categories that are sufficiently large to avoid the hazard of small subgroups. With regard to generalisability, our findings might not apply to an unselected population with atrial fibrillation, given the selection that occurs when enrolling patients in clinical trials.

#### Conclusions

In this population with atrial fibrillation on oral anticoagulation therapy, polypharmacy (≥5 drugs) was observed in three quarters of patients. The extent of comorbidity increased with greater numbers of

concomitant drugs, which was irrespective of regional prescription patterns. Mortality, stroke, and major bleeding were also more frequent with increasing numbers of drugs. As for a potential differential response to anticoagulation therapy in this context, we observed that apixaban was superior to warfarin in terms of efficacy, regardless of the number of drugs taken, whereas its magnitude of benefit on major bleeding decreased with higher numbers of concomitant drugs. Important differences in the comorbidity profile could account for this, and it did not appear that warfarin or apixaban potentiating drugs (CYP3A4, P-glycoprotein inhibitors) explained this observed treatment interaction. In summary, apixaban is more effective than and is at least as safe as warfarin in patients with atrial fibrillation, regardless of polypharmacy.

**Contributors:** All the authors made substantial contributions to the conception and design of the work, and the acquisition and interpretation of data for the work. DMW and LT conducted the data analysis. JIF, MAB, and FWAV drafted the work and all authors revised it critically for important intellectual content and approved of the final version for submission. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors had full access to the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. CBG is the study guarantor.

**Funding:** The ARISTOTLE study was supported by Bristol-Myers Squibb and Pfizer. The sponsors did not have any role in the study design, collection, analysis, and interpretation of the data; in writing the report; or in the decision to submit the article for publication.

**Competing interests:** All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: JIF has received consulting fees/honorariums from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo; MAB has received consulting fees/honorariums from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo; DMW, LT, FL, and JBW have nothing to report; RDL reports consulting fees/honorariums from Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Merck, Pfizer, and Portola, and research grants from Bristol-Myers Squibb and GlaxoSmithKline; DX reports research grants to his institution from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cadila Pharma, Pfizer, and Sanofi-Aventis; SH reports consulting fees/honorariums from AstraZeneca, Bayer, Boehringer Ingelheim, and Pfizer, and research grants from GlaxoSmithKline; LW reports consulting fees/honorariums from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Pfizer, and research grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Merck/Schering-Plough, Pfizer, and Roche Diagnostics; JHA reports consulting fees/honorariums from Bristol-Myers Squibb, CSL Behring, Portola, and Somahlution, and research grants from Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, Regado Biosciences, Sanofi, Tenax Therapeutics, and Vivus Pharmaceuticals; CBG reports consulting fees/honorariums from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Hoffman LaRoche, Janssen, Medtronic, Novartis, Pfizer, Sanofi-Aventis, Takeda, and The Medicines Company, and research grants from Armethion, AstraZeneca, Bayer, Boehringer Ingelheim, and Bristol-Myers Squibb; FWAV reports consulting fees/honorariums from AstraZeneca, BMS/Pfizer, Bayer, Daiichi-Sankyo, and Boehringer-Ingelheim.

**Ethical approval:** The ARISTOTLE study was approved by the appropriate ethics committees at all sites; all patients provided written informed consent.

**Data sharing:** No additional data available.

The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>.

- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015;385:117-71. doi:10.1016/S0140-6736(14)61682-2.
- Nieuwlaat R, Olsson SB, Lip GYH, et al. Euro Heart Survey Investigators Euro Heart Survey on Atrial Fibrillation. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. *Am Heart J* 2007;153:1006-12. doi:10.1016/j.ahj.2007.03.008.
- Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. *Heart* 2013;99:127-32. doi:10.1136/heartjnl-2012-302843.
- Singh S, Bajorek B. Pharmacotherapy in the ageing patient: the impact of age per se (a review). *Ageing Res Rev* 2015;24:99-110. doi:10.1016/j.arr.2015.07.006.
- Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: a cross-sectional analysis. *Drugs Aging* 2009;26:493-503. doi:10.2165/00002512-200926060-00006.
- Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. *J Clin Epidemiol* 2012;65:989-95. doi:10.1016/j.jclinepi.2012.02.018.
- Herr M, Robine JM, Pinot J, Arvieu JJ, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. *Pharmacoepidemiol Drug Saf* 2015;24:637-46. doi:10.1002/pds.3772.
- Wang R, Chen L, Fan L, et al. Incidence and effects of polypharmacy on clinical outcomes among patients aged 80+: a five-year follow-up study. *PLoS One* 2015;10:e0142123. doi:10.1371/journal.pone.0142123.
- Proietti M, Raparelli V, Olshansky B, Lip GYH. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. *Clin Res Cardiol* 2016;105:412-20. doi:10.1007/s00392-015-0936-y.
- Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. *Circulation* 2016;133:352-60. doi:10.1161/CIRCULATIONAHA.115.018544.
- Abdelhafiz AH, Wheeldon NM. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. *Am J Geriatr Pharmacother* 2008;6:1-11. doi:10.1016/j.amjopharm.2008.03.005.
- Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of anticoagulation therapy in well-informed older patients. *Arch Intern Med* 2004;164:2044-50. doi:10.1001/archinte.164.18.2044.
- Donzé J, Clair C, Hug B, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. *Am J Med* 2012;125:773-8. doi:10.1016/j.amjmed.2012.01.033.
- Leiss W, Méan M, Limacher A, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. *J Gen Intern Med* 2015;30:17-24. doi:10.1007/s11606-014-2993-8.
- Goldhaber SZ, Eriksson H, Kakkar A, et al. Influence of polypharmacy on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. *Circulation* 2015;132:A12422.
- Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. *Arch Intern Med* 1996;156:409-16. doi:10.1001/archinte.1996.00440040081009.
- Wehinger C, Stöllberger C, Länger T, Schneider B, Finsterer J. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. *Stroke* 2001;32:2246-52. doi:10.1161/hs1001.097090.
- Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. *N Engl J Med* 2011;364:806-17. doi:10.1056/NEJMoa1007432.
- Granger CB, Alexander JH, McMurray JJJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;365:981-92. doi:10.1056/NEJMoa1107039.

- 20 Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. *Eur Heart J* 2014;35:1864-72. doi:10.1093/eurheartj/ehu046.
- 21 Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOS study. *Eur J Intern Med* 2011;22:597-602. doi:10.1016/j.ejim.2011.08.029.
- 22 Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. *Br J Clin Pharmacol* 2007;63:187-95. doi:10.1111/j.1365-2125.2006.02744.x.
- 23 Lopes RD, Alexander JH, Al-Khatib SM, et al. ARISTOTLE Investigators. Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. *Am Heart J* 2010;159:331-9. doi:10.1016/j.ahj.2009.07.035.
- 24 World Health Organization Collaborating Centre for Drug Statistics Methodology (WHOC). 2015. www.whocc.no/atc\_ddd\_index.
- 25 US Food and Drug Administration (FDA). 2014. www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm.
- 26 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). *Chest* 2008;133(suppl):160S-98S. doi:10.1378/chest.08-0670.
- 27 Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. *Thromb Haemost* 1993;69:236-9.
- 28 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost* 2005;3:692-4. doi:10.1111/j.1538-7836.2005.01204.x.
- 29 Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med* 1999;131:492-501. doi:10.7326/0003-4819-131-7-199910050-00003.
- 30 Lip GYH, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. *Europace* 2014;16:308-19. doi:10.1093/europace/eut373.
- 31 Halperin JL, Hankey GJ, Wojdyla DM, et al. ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with non-valvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). *Circulation* 2014;130:138-46. doi:10.1161/CIRCULATIONAHA.113.005008.
- 32 Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. *J Am Coll Cardiol* 2014;63:2141-7. doi:10.1016/j.jacc.2014.02.549.
- 33 Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. *Thromb Haemost* 2010;104:1099-105. doi:10.1160/TH10-07-0491.
- 34 White HD, Gruber M, Feysi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. *Arch Intern Med* 2007;167:239-45. doi:10.1001/archinte.167.3.239.
- 35 Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population. *Heart* 2005;91:472-7. doi:10.1136/hrt.2004.042465.
- 36 Prins MH, Lensing AWA, Bauersachs R, et al. EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. *Thromb J* 2013;11:21. doi:10.1186/1477-9560-11-21.
- 37 Singh M, Stewart R, White H. Importance of frailty in patients with cardiovascular disease. *Eur Heart J* 2014;35:1726-31. doi:10.1093/eurheartj/ehu197.
- 38 Fried LP, Tangen CM, Walston J, et al. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56:M146-56. doi:10.1093/gerona/56.3.M146.
- 39 Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the aging patient: management of hypertension in octogenarians. *JAMA* 2015;314:170-80. doi:10.1001/jama.2015.7517.

## Web appendix: Supplementary materials